Trial · NCT00874432
Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease
NCT00874432, Phase 2, Completed, University of Wisconsin, Madison; results first posted 2020-09-23
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease. Trials, record NCT00874432. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00874432
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease
- NCT number
- NCT00874432
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 43 participants, actual
- Lead sponsor
- University of Wisconsin, Madison
- Conditions
- Cardiovascular Disease, Chronic Kidney Disease
- Interventions
- angiotensin converting enzyme inhibitor, lisinopril
- First posted
- 2009-04-02
- Last updated
- 2020-10-27
- Results first posted
- 2020-09-23
- Limitations and caveats
There is limited data for this study, the PI is now in private practice and some raw data no longer exists to answer this outcome. We have done our due diligence to populate this record with data that remains.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Aortic Pulse Wave Velocity (PWV) | up to 12 months | PWV will be measured in patients over age 60 with stage 3 CKD and age matched controls without CKD. |
| Secondary | Mean Vascular Stiffness As Measured by PWV | baseline and 12 months | Comparison between Participants with Stage 3 Chronic Kidney Disease (CKD) and age matched Controls without CKD. The numbers reported are the mean of all the participants in the group at two points in time - the baseline and at 12 months for CFPWV, CBPWV, and CRPWV. Carotid-Femoral Pulse Wave Velocity (CFPWV) Carotid-Brachial Pulse Wave Velocity (CBPWV) Carotid-Radial Pulse Wave Velocity (CRPWV) |
| Secondary | Change in Blood Pressure From Baseline to 12 Months | up to 12 months | Change in Blood Pressure will be used to measure the effect of ACE-inhibitors on the clinical markers of Cardiovascular Disease in participants with stage 3 CKD. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Aortic Pulse Wave Velocity (PWV) | up to 12 months | Comparison of the baseline pulse wave velocity measures between the two groups (CKD vs no CKD) prior to intervention with ACE inhibitor. Data analyzed is from 32 participants due to drop out either from study self withdrawal (3) or ineligibility (1 = BP too low to start medication) and 7 without adequate testing data available for analysis. | m/s | MEAN |
| SECONDARY | Mean Vascular Stiffness As Measured by PWV | baseline and 12 months | Participants in each arm that had measurements for both baseline and 12 months | m/s | MEAN |
| SECONDARY | Change in Blood Pressure From Baseline to 12 Months | up to 12 months | There is limited data for this study, the PI is now in private practice and the raw data no longer exists to answer this outcome. We have done our due diligence to populate this record with data that remains. |
Source ClinicalTrials.gov
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Aortic Pulse Wave Velocity (PWV) | Chronic Kidney Disease | Carotid-Femoral Pulse Wave Velocity | 9.90 | Standard Deviation 1.12 | m/s |
| Aortic Pulse Wave Velocity (PWV) | Age Matched Control | Carotid-Femoral Pulse Wave Velocity | 9.96 | Standard Deviation 2.52 | m/s |
| Aortic Pulse Wave Velocity (PWV) | Chronic Kidney Disease | Carotid-Brachial Pulse Wave Velocity | 7.62 | Standard Deviation 1.76 | m/s |
| Aortic Pulse Wave Velocity (PWV) | Age Matched Control | Carotid-Brachial Pulse Wave Velocity | 8.57 | Standard Deviation 1.46 | m/s |
| Aortic Pulse Wave Velocity (PWV) | Chronic Kidney Disease | Carotid-Radial Pulse Wave Velocity | 9.03 | Standard Deviation 2.12 | m/s |
| Aortic Pulse Wave Velocity (PWV) | Age Matched Control | Carotid-Radial Pulse Wave Velocity | 8.38 | Standard Deviation 1.76 | m/s |
| Mean Vascular Stiffness As Measured by PWV | Chronic Kidney Disease-ACE-I | CBPWV Baseline | 7.87 | Standard Deviation 1.70 | m/s |
| Mean Vascular Stiffness As Measured by PWV | Chronic Kidney Disease | CBPWV Baseline | 6.28 | Standard Deviation NA | m/s |
| Mean Vascular Stiffness As Measured by PWV | Age Matched Control-ACE-I | CBPWV Baseline | 9.14 | Standard Deviation 0.82 | m/s |
| Mean Vascular Stiffness As Measured by PWV | Age Matched Control | CBPWV Baseline | 8.17 | Standard Deviation 1.61 | m/s |
1 to 10 of 30Source ClinicalTrials.gov
See all 30 results by groupParticipant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Chronic Kidney Disease-ACE-I | 8 | |
| Overall Study | STARTED | Chronic Kidney Disease | 4 | |
| Overall Study | STARTED | Age Matched Control-ACE-I | 17 | |
| Overall Study | STARTED | Age Matched Control | 14 | |
| Overall Study | COMPLETED | Chronic Kidney Disease-ACE-I | 5 | |
| Overall Study | COMPLETED | Chronic Kidney Disease | 2 | |
| Overall Study | COMPLETED | Age Matched Control-ACE-I | 9 | |
| Overall Study | COMPLETED | Age Matched Control | 11 | |
| Overall Study | NOT COMPLETED | Chronic Kidney Disease-ACE-I | 3 | |
| Overall Study | NOT COMPLETED | Chronic Kidney Disease | 2 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events32
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Uticaria | Skin and subcutaneous tissue disorders | Chronic Kidney Disease-ACE-I | 0 | 8 | |
| other | Uticaria | Skin and subcutaneous tissue disorders | Chronic Kidney Disease | 1 | 4 | |
| other | Uticaria | Skin and subcutaneous tissue disorders | Age Matched Control-ACE-I | 0 | 17 | |
| other | Uticaria | Skin and subcutaneous tissue disorders | Age Matched Control | 0 | 14 | |
| other | Dizziness | Nervous system disorders | Chronic Kidney Disease-ACE-I | 2 | 8 | |
| other | Dizziness | Nervous system disorders | Chronic Kidney Disease | 0 | 4 | |
| other | Dizziness | Nervous system disorders | Age Matched Control-ACE-I | 0 | 17 | |
| other | Dizziness | Nervous system disorders | Age Matched Control | 0 | 14 | |
| other | Lip Parasthesia | Nervous system disorders | Chronic Kidney Disease-ACE-I | 0 | 8 | |
| other | Lip Parasthesia | Nervous system disorders | Chronic Kidney Disease | 0 | 4 |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 adverse eventsAdverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Chronic Kidney Disease-ACE-I | 0 | 8 |
| Total, all-cause mortality | Chronic Kidney Disease | 0 | 4 |
| Total, all-cause mortality | Age Matched Control-ACE-I | 0 | 17 |
| Total, all-cause mortality | Age Matched Control | 0 | 14 |
| Total, other adverse events | Chronic Kidney Disease-ACE-I | 2 | 8 |
| Total, other adverse events | Chronic Kidney Disease | 1 | 4 |
| Total, other adverse events | Age Matched Control-ACE-I | 3 | 17 |
| Total, other adverse events | Age Matched Control | 1 | 14 |
| Total, serious adverse events | Chronic Kidney Disease-ACE-I | 0 | 8 |
| Total, serious adverse events | Chronic Kidney Disease | 0 | 4 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers34
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00874432
GET https://conductscience.org/api/trials/v1/NCT00874432/results?page=2